Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-106599
Filing Date
2025-08-11
Accepted
2025-08-11 16:32:31
Documents
68
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q xene-20250630.htm   iXBRL 10-Q 2608571
2 EX-10.1 xene-ex10_1.htm EX-10.1 91530
3 EX-10.2 xene-ex10_2.htm EX-10.2 188468
4 EX-31.1 xene-ex31_1.htm EX-31.1 16746
5 EX-31.2 xene-ex31_2.htm EX-31.2 16742
6 EX-32.1 xene-ex32_1.htm EX-32.1 12092
7 EX-32.2 xene-ex32_2.htm EX-32.2 11532
8 GRAPHIC img3581121_0.jpg GRAPHIC 240987
9 GRAPHIC img3581121_1.jpg GRAPHIC 240987
  Complete submission text file 0000950170-25-106599.txt   9904913

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT xene-20250630.xsd EX-101.SCH 898874
71 EXTRACTED XBRL INSTANCE DOCUMENT xene-20250630_htm.xml XML 1796161
Mailing Address 200 - 3650 GILMORE WAY BURNABY British Columbia, Canada
Business Address 200 - 3650 GILMORE WAY BURNABY British Columbia, Canada (604) 484-3300
Xenon Pharmaceuticals Inc. (Filer) CIK: 0001582313 (see all company filings)

EIN.: 980661854 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36687 | Film No.: 251202501
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)